The present invention relates to the use of compounds which display activity as inhibitors of the human N-myristoyl transferases (NMT) in the treatment of MYC addicted cancers, such as, for example, cancers comprising MYC overexpression. The present invention also relates to the use of compounds which display activity as inhibitors of NMT, in combination with one or more other therapeutic agents, in the treatment of MYC addicted cancers and/or MYC dysregulated cancers.

The invention relates to biosensor for detecting and/or quantifying exercise and disease-risk associated enzymes in a biological sample and related methods. The biosensor includes a solid support and a nanostructure with a metallic core and a phospholipid shell capable of binding to a lecithin:cholesterol acyltransferase (LCAT) activator (BL-NP).

The present application demonstrates that sirtuin 4 (SIRT4) acts as a cellular lipoamidase that negatively regulates pyruvate dehydrogenase complex (PDHC) activity through hydrolysis of its lipoamide cofactors.

The present invention relates to compositions and methods for inhibiting DHHC3 palmitoyltransferase for treating cancer. Described herein, are methods of inhibiting expression or activity of programmed death-ligand 1 (PD-L1) in a cell of a subject, e.g., a human subject, in need thereof are carried out by administering to the subject an effective amount of a palmitoyltransferase inhibitor, thereby inhibiting the expression or activity of PD-L1 in the subject. The palmitoyltransferase comprises an Asp-His-His-Cys motif (DHHC)-type protein. Exemplary DHHC-type proteins include DHHC3, DHHC5, DHHC7, and DHHC17.

The present disclosure relates generally to methods of treating human patients suffering from a liver disease or condition. The disclosure also provides diagnostic methods for determining the stage or status of the liver disease or condition and monitoring methods for assessing the effectiveness of a treatment, using serum protein, metabolites or bile acid markers.

The present application demonstrates that sirtuin 4 (SIRT4) acts as a cellular lipoamidase that negatively regulates pyruvate dehydrogenase complex (PDHC) activity through hydrolysis of its lipoamide cofactors.

The present invention relates to the use of levels of the amount or concentration of the ghrelin-O-acyltransferase (GOAT) enzyme or of the mRNA encoding this protein, obtained ex vivo from a biological sample isolated from a subject, as an efficient tool for obtaining data that can be used in the clinical diagnosis of prostate cancer.

Advantage is taken of macrolide antibiotics' complexation with free cholesterol to yield fluorescent complexes to determine the levels of free cholesterol, total cholesterol, or lecithin: cholesterol acyl transferase (LCAT) in serum or plasma or fractions thereof or to determine the level of cholesterol esterase in a sample.

The present invention provides a method of diagnosing endometriosis and/or infertility in a subject, comprising: a) obtaining a sample from the subject; b) detecting a level of expression of a SIRT1 gene and/or protein in the sample; c) detecting a level of expression of a BCL6 gene and/or protein in the sample; d) comparing the level of expression detected in (b) with the level of expression of a SIRT1 gene and/or protein in a sample obtained from a control subject or a population of control subjects; e) comparing the level of expression detected in (c) with the level of expression of a BCL6 gene and/or protein in a sample obtained from a control subject or a population of control subjects; and f) diagnosing the subject as having infertility when the subject has a level of expression of the SIRT1 gene and/or protein greater than the level of expression of the SIRT1 gene and/or protein of the control subject or population of control subjects and also has a level of expression of the BCL6 gene and/or protein that is greater than the level of expression of the BCL6 gene and/or protein of the control subject or population of control subjects.

High levels of nuclear NMT1 are associated with longer relapse free survival in ER positive breast cancer patients. Both low levels of cytosolic and nuclear NMT1 correlated to very poor clinical outcomes. NMT2 also plays an important function in breast cancer signalling, regulated through phosphorylation. For example, NMT2 phosphorylation status is a key element in the progression of ER+ breast cancer cells. Specifically, nuclear localization of NMT2 is associated with poor outcomes in breast cancer patients.